SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors analyze the potential impact of an upcoming earnings report, with community members actively discussing expectations for guidance and margin recovery. Bullish sentiment seems to be building with some traders anticipating a positive surprise and a potential stock buyback announcement. The stock's performance is also being viewed in the context of broader healthcare sector trends and regulatory scrutiny.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors eagerly await earnings, with community chatter focused on potential leaks and speculating on the company's revenue and guidance. Bullish sentiment is fueled by the fintech sector's strength and SoFi's long-term fundamentals, though some anticipate a post-earnings sell-off. Discussions also revolve around SoFi's potential S&P 500 inclusion and expansion into crypto offerings.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin is trending, with the community actively chanting "caw caw" and emphasizing its fully circulated, community-driven nature. Its multichain presence across Solana, BSC, Cronos, and Ethereum (BASE) is a key talking point, with some mentioning potential staking opportunities. The coin's deflationary mechanism and partnerships are also being highlighted by the community.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as traders digest the company's recent earnings report, which beat expectations. Community members are expressing bullish sentiment and discussing the positive guidance, while some remain concerned about potential dividend cuts and broader economic headwinds. The stock's recent price movement and options activity are also drawing attention.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community discusses the potential launch of the first HBAR ETF, speculating on institutional adoption and possible price implications. Some community members believe enterprise use cases are scaling, positioning HBAR as an undervalued Layer-1 solution, while others express caution, citing previous price volatility.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to anticipation surrounding its upcoming earnings report, with community members actively discussing potential outcomes and market reactions. Bullish investors are optimistic about new partnerships and global market implementation, while others express concern over the stock's historical performance post-earnings and crowded competition in the fintech sector. Technical analysis suggests a potential breakout, but caution remains as some foresee a continued collapse cycle.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene is trending as investors discuss potential catalysts, including strong Medicare growth and the possibility of positive earnings mirroring UnitedHealth's success. The community is weighing whether to hold through earnings, considering potential government shutdown impacts and ACA subsidy extensions. Some traders believe the stock is oversold and presents a buying opportunity due to its undervalued status and potential for a recovery.

AIFU, Inc. engages in the provision of agency services and insurance claims adjusting services. It operates through the Insurance Agency and Claims Adjusting segments. The Insurance Agency segment includes providing agency services for insurance products and life insurance products. The Claims Adjusting segment provides pre-underwriting survey services, claims adjusting services, disposal of residual value services, loading and unloading supervision services, and consulting services. The company was founded by Yin An Hu and Qiu Ping Lai in 1998 and is headquartered in Guangzhou, China.

AIFU Inc. - Ordinary Shares - Class A

AIX Inc. - ADR

AIX Inc. - ADR ($AIFU) is trending as traders discuss its potential, noting its low float and AI-driven approach to financial services. Community members are speculating on potential squeezes and the stock's potential for a significant breakout, drawing comparisons to other high-momentum stocks. Some investors are also watching for spillover effects from broader positive sentiment around Chinese stocks or specific AI-related catalysts.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco (CCJ) is trending as Elliott Wave analysis indicates a strong impulse structure unfolding from an April 2025 base, suggesting a bullish wave. Community discussions revolve around its breakout potential and key support levels, particularly the 20 EMA line. Broader context includes positive sentiment for nuclear energy driven by global demand and strategic developments in Singapore and the US DOE.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the following segments: FPL and NEER. The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEra Energy is trending following news of a partnership with Google to restart a nuclear power plant in Iowa, aiming to power Google's AI data centers with carbon-free energy. The community is discussing the implications of this deal, particularly the revival of nuclear energy and its role in clean energy strategies for tech companies. Positive after-hours movement suggests growing confidence in nuclear power's resurgence and NextEra's strategic positioning in the renewable energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OS Therapies (NYSE-A: $OSTX) announced that the company held a successful Scientific Advice Meeting with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in July and submitted an Innovative Licensing and Access Pathway (ILAP) application to advance regulatory approval for OST-HER2 in preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. 
 
OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1. 
 
The MHRA recommended applying for Project Orbis when submitting for regulatory approval to align the UK’s Marketing Authorization Application process with the US FDA’s Biologics Licensing Application (BLA) Accelerated Approval Program. Project Orbis is an FDA-led global initiative that enables simultaneous submission and review of oncology products across multiple countries, potentially accelerating patient access to promising cancer treatments. 
 
Highlights from today’s news release include: 
 
- Positive feedback received from the UK MHRA Scientific Advice Meeting held in July 2025. 
 
- ILAP application submitted to begin UK regulatory approval process for OST-HER2. 
 
- European Medicines Agency rapporteur meeting scheduled for October 2025 to initiate EU-wide Marketing Authorization via the Centralized Procedure. 
 
Paul Romness, MPH, CEO of OS Therapies, remarked, “We are pleased with the outcome of our meeting with MHRA in the UK and are working to ensure that we provide FDA and MHRA everything they need to be able to rapidly approve OST-HER2 for metastatic osteosarcoma patients. We have officially begun the regulatory process in Europe as the next part of our regulatory strategy to bring this novel immunotherapy to osteosarcoma patients worldwide.” 
 
Read the full release at: https://ir.ostherapies.com/news-events/press-releases/detail/71/os-therapies-receives-positive-feedback-from-uk-mhra 
 
Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. 
 
Learn more about OS Therapies’ work at https://www.ostherapies.com and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com. 
 
Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/os-therapies-1 $THTX $CGTX

David Shapiro

Brogley Panzarella

Slade Magat

Xylia Fluetsch

Illescas Gibes

Refugio Bergstrom

top moon

Nils Vrooman

Cal Dwan

Pablo Rodriguez

Ariana Storck

Joseph Forbes

Jack Tharpe

Heidi Campbell

Guillermo Oneill

Amie Fazio

Virgil Bowen

Clarice Hasselman

Greg Harrison

Stephan Breeden

Guadalupe Giese

Renee Blankenship

Nina Studdard

James Williams

OS Therapies is dedicated to developing innovative cancer treatments, including immunotherapies that harness the immune system to fight tumors and advanced drug technologies designed to deliver chemotherapy more precisely to cancer cells while reducing side effects.

B2idigital

OS Therapies, Inc. (NYSE-A: OSTX) Profile on B2i Digital

MHRA seeks to harmonize UK &amp; US regulatory review via Project Orbis EMA Rapporteur Scientific Advice Meeting scheduled for October 2025 New......

OS Therapies, Inc.

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

A documentary featuring OS Therapies' groundbreaking OST-HER2 immunotherapy, has received two 2025 Daytime Emmy nominations: Outstanding Daytime Special and Outstanding Writing Team for a Daytime Non-Fiction Program! This recognition underscores the critical importance of advancing innovative treatments for diseases like osteosarcoma. Your awareness and support for these pioneers help elevate the conversation around critical medical breakthroughs.

Ostherapies

Home | OS Therapies

StockTwits Web

OS Therapies Inc

Theratechnologies Inc.

Cognition Therapeutics Inc

) announced that the company held a successful Scientific Advice Meeting with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in July and submitted an Innovative Licensing and Access Pathway (ILAP) application to advance regulatory approval for OST-HER2 in preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. 
 
OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at 

. 
 
The MHRA recommended applying for Project Orbis when submitting for regulatory approval to align the UK’s Marketing Authorization Application process with the US FDA’s Biologics Licensing Application (BLA) Accelerated Approval Program. Project Orbis is an FDA-led global initiative that enables simultaneous submission and review of oncology products across multiple countries, potentially accelerating patient access to promising cancer treatments. 
 
Highlights from today’s news release include: 
 
- Positive feedback received from the UK MHRA Scientific Advice Meeting held in July 2025. 
 
- ILAP application submitted to begin UK regulatory approval process for OST-HER2. 
 
- European Medicines Agency rapporteur meeting scheduled for October 2025 to initiate EU-wide Marketing Authorization via the Centralized Procedure. 
 
Paul Romness, MPH, CEO of OS Therapies, remarked, “We are pleased with the outcome of our meeting with MHRA in the UK and are working to ensure that we provide FDA and MHRA everything they need to be able to rapidly approve OST-HER2 for metastatic osteosarcoma patients. We have officially begun the regulatory process in Europe as the next part of our regulatory strategy to bring this novel immunotherapy to osteosarcoma patients worldwide.” 
 
Read the full release at: 

 
 
Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. 
 
Learn more about OS Therapies’ work at 

 and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com. 
 
Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of 

Explore OS Therapies’ full company profile at https://b2idigital.com/os-therapies-1 for comprehensive insights into their OST‑HER2 therapy, regulatory milestones, and strategic initiatives.

Explore OS Therapies’ full company profile at 

 for comprehensive insights into their OST‑HER2 therapy, regulatory milestones, and strategic initiatives.

@B2iDigital @waterseid Why did you tag TXTX?